Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Johnson, Constance Margaret

University Of Texas Hlth Sci Ctr Houston
United States

Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy 3R01CA245054-05S1 Rachel Altshuler, Ph.D.
Johnson, Constance Margaret

University Of Texas Hlth Sci Ctr Houston
United States

Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy 3R01CA245054-05S1 Rachel Altshuler, Ph.D.
Johnson, Constance Margaret

University Of Texas Hlth Sci Ctr Houston
United States

Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy 3R01CA245054-05S1 Rachel Altshuler, Ph.D.
Johnson, Jeremy James

University Of Illinois At Chicago
United States

Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer 5R37CA227101-07 Amit Kumar, Ph.D.
Judge, Andrew Robert

University Of Florida
United States

The Complement System and Cancer Cachexia 5R01AR081648-04 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Judge, Andrew Robert

University Of Florida
United States

The Complement System and Cancer Cachexia 5R01AR081648-04 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Justilien, Verline

Mayo Clinic Jacksonville
United States

ECT2 Isoform Switch in Pancreatic Cancer. 1R21CA296671-01 Matthew Young, Ph.D.
Kachnic, Lisa A.

Columbia University Health Sciences
United States

Columbia University NCI Community Oncology Research Program 3UG1CA189960-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Kachnic, Lisa A.

Columbia University Health Sciences
United States

Columbia University NCI Community Oncology Research Program 3UG1CA189960-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Kahalley, Lisa Schum

Baylor College Of Medicine
United States

Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. 3R01CA249988-05S3 Rachel Altshuler, Ph.D.
Kahalley, Lisa Schum

Baylor College Of Medicine
United States

Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. 3R01CA249988-05S3 Rachel Altshuler, Ph.D.
Kahalley, Lisa Schum

Baylor College Of Medicine
United States

Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. 3R01CA249988-05S3 Rachel Altshuler, Ph.D.
Kahalley, Lisa Schum

Baylor College Of Medicine
United States

Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. 3R01CA249988-05S3 Rachel Altshuler, Ph.D.
Kalpathy-Cramer, Jayashree

University Of Colorado Denver
United States

AI algorithm development for cervical cancer screening in low resource settings 1R21CA305472-01 Nicholas Hodges, Ph.D.
Kanarek, Naama

Boston Children'S Hospital
United States

Mechanistic Study of Methotrexate-Induced Oxidative Distress in Neurons and the CSF 5R01CA282477-02 John Clifford, Ph.D.